NR3C1 and neoplasm: Dexamethasone, betamethasone, prednisolone, or triamcinolone restored cisplatin-resistant cancer cell survival and MEK-ERK phosphorylation, whereas treatment with the MAST1 inhibitor diminished the elevated MEK-ERK activity and cisplatin resistance in GR agonist-treated tumor cells (Fig. 8a, b; Supplementary Figs. 7a–c and 8a).